Acceleron Pharma Inc:
Developing TGF-beta therapeutics to treat serious and rare diseases. Lead therapeutic candidate in hematology, luspatercept, under a global partnership with Celgene, reported positive Phase 3 MEDALIST and BELIEVE trial results, and continues to advance multiple Ph2 and Ph3 trials for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. The Company has additional candidates advancing across multiple Phase 2 clinical trials for neuromuscular and pulmonary diseases.
Phase III, Phase l or ll
128 Sidney Street
Cambridge, MA 02139
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by